Scientists Found a New Way to Fight the Zika Virus

The mosquito-borne Zika virus still has no approved drug or vaccine to stop it. Now a team of Italian researchers says it has found a molecule that jams a piece of machinery the virus needs to copy itself, which could become the first targeted treatment for the disease, the organization announced.

The molecule, named IRBM-Z-2, is a novel and potent allosteric inhibitor that targets the Zika virus protease known as NS2B-NS3. Instead of attacking the enzyme's active site, it binds to a previously uncharacterized pocket on the protease's surface and shuts the enzyme down from the side. In biochemical and cellular assays it suppressed protease activity, and in animal models it showed significant antiviral effects. The compound also showed a favorable safety and pharmacokinetic profile, supporting its potential for clinical development, according to findings published in the journal Nature Communications.

That profile matters because Zika has resisted every effort to produce a medical countermeasure. The virus poses a serious public health threat due to its association with severe neurological complications, and mosquitoes keep spreading it through tropical and subtropical regions. An effective antiviral would fill a gap that has sat open since the virus first made global headlines.

Why the protease is the right target

Like all viruses, Zika needs its own enzymes to replicate inside human cells, and the NS2B-NS3 protease is one of the most important. The IRBM team's insight was to look for a binding site nobody had characterized before. Allosteric inhibitors, which attach away from the active site, can be more selective than drugs aimed at the active pocket itself, because these secondary pockets tend to differ more between viral and human enzymes. The researchers confirmed the new site's existence through mechanistic enzymology, then built a molecule shaped to fit it.

Drug hunters often struggle with viral proteases because the active site looks similar across many enzymes. Finding a previously uncharacterized allosteric site gave the team a handle that competing approaches did not have, and the resulting inhibitor suppressed the protease in both biochemical and cell-based tests before moving into animal studies, where the antiviral activity held up.

It could work against more than Zika

Zika belongs to the flavivirus family, which also includes dengue, yellow fever, and West Nile virus. Because the NS2B-NS3 protease is shared across these relatives, the mechanism behind IRBM-Z-2 may extend to them as well, suggesting broader therapeutic potential, according to the announcement. A single drug scaffold that could be adapted against several mosquito-borne viruses would be a significant prize for public health.

How the team found it

IRBM, a research organization specializing in early drug discovery, said its scientists combined high-content phenotypic screening with computational modeling, mechanistic enzymology, iterative medicinal chemistry, and ADME profiling. The integrated pipeline let the team move rapidly from initial hit identification to preclinical candidate selection, the stage where a molecule is judged ready for the long road toward human trials.

The project was funded by the Region of Lazio and grew out of a collaborative initiative originating from CNCCS, a public-private consortium that brings together IRBM, Italy's National Research Council, the Istituto Superiore di Sanita, and the University of La Sapienza. CNCCS operates as a lead factory for drug discovery programs, pairing a chemical compound repository with a high-throughput screening platform, with a particular focus on rare, neglected, and poverty-related diseases.

What the scientists said

Carlo Toniatti, IRBM's chief scientific officer, called the discovery "an important milestone in antiviral drug development" in a statement, saying the team had "delivered a novel ZIKV protease inhibitor with compelling preclinical activity" by combining "cutting-edge medicinal chemistry and integrated screening technologies."

Matteo Liguori, IRBM's chief executive and founder, said the project "demonstrates the impact that effective public-private partnerships can have on advancing new therapies," adding that the organization aims to act as "a bridge between academic discoveries and the clinic." Details of the work were reported by IRBM in its announcement of the findings, and more on the organization's research programs is available at irbm.com.

What comes next

The molecule now sits at preclinical candidate selection, the point where laboratory promise has to survive the scrutiny of formal development. The favorable safety and pharmacokinetic profile gives it a plausible path toward human studies, though years of testing stand between a lead compound and an approved medicine. The team said the work opens a promising path toward targeted antiviral therapies that could fill a critical gap in global public health preparedness, and that it reinforces the joint commitment of CNCCS and IRBM to tackle rare and neglected diseases with new science.